. 2021 Jun 22;62(7):24. doi: 10.1167/iovs.62.7.24

Table 1.

Baseline Characteristics of Patients

Patient	Disease	Age (y)	Sex	BMI	mD (dB)	ROP (db/y)	IOP (mm Hg)	HT	HC	Topical Medication	Systemic Medication
466	POAG	84	M	25.64	−9.19	−0.45	10			Bimatoprost^*; dorzolamide,^† timolol^‡	Prednisolone,^¶ alendronic acid
700	POAG	73	F	22.1	−1.79	0.61	18			Brinzolamide,^† timolol,^‡ tafluprost^*	None
576	POAG	80	M	28.41	−16.1	0.10	17	+	+	Dorzolamide,^† tafluprost^*	Valsartan^**
665	POAG	73	F	27.97	−2.68	−1.42	12	+	+	Latanoprost,^* brinzolamide,^† timolol,^‡ polyvidon^§	Irbesartan,^** metoprolol,^‡ Rosuvastatin^††
769	POAG	80	M	27.99	−26.43	0.20	20			Latanoprost,^* brinzolamide,^† brimonidine^ǁ	None
810	POAG	69	F	26.99	−11.1	−0.31	18	+		None (intolerant)	Metoprolol,^‡ valsartan,^** simvastatin^††
464	POAG	70	F	27.44	−5.57	−1.36	21			Timolol,^‡ travoprost^*	None
615	POAG	71	F	27.73	−25.31	0.55	10			Dorzolamide,^† timolol,^‡ Bimatoprost^*	None
1016	POAG	78	M	22.58	−18.98	−3.15	11			Dorzolamide,^† Timolol,^‡ travoprost^*	Atorvastatin,^†† valsartan,^** lithium carbonate, mirtazapine,^‡‡ quetiapine^§§
412	Cataract	87	M	23.95	N/A	N/A	13	+		None	Losartan,^** amlodipine,^ǁǁ simvastatin,^†† prednisolone^¶
449	Cataract	86	M	17.99	N/A	N/A	16			None	Metoprolol,^‡ valsartan,^** gemfibrozil^¶¶
450	Cataract	81	V	21.08	N/A	N/A	22			None	Clopidogrel^##
579	Cataract	83	M	23.5	N/A	N/A	16	+		None	Carbasalate calcium,^*** metoprolol,^‡ simvastatin,^†† nifedipine^ǁǁ
585	Cataract	84	M	20.41	N/A	N/A	16	+	+	None	Barnidipine,^ǁǁ enalapril,^††† metoprolol,^‡ spironolactone^‡‡‡
809	Cataract	60	M	24.49	N/A	N/A	18			None	None
447	Cataract	68	F	24.09	N/A	N/A	14		+	None	Simvastatin^††
770	Cataract	75	F	24.09	N/A	N/A	20			None	Carbasalate calcium,^* irbesartan,^ verapamil,^ǁǁ ibandronic acid
1042	Cataract	79	M	23.39	N/A	N/A	10			None	None
1060	Cataract	55	M	30.39	N/A	N/A	18			None	None

Glaucoma disease severity was assessed with Humphrey visual field test, and expressed as the amount of mD dB. ROP is expressed as the dB loss per year. A positive rate of progression indicates that the patient scored better during the current visual field test in comparison to results of a previous test.

dB, decibels; HT, hypertension; HC, hypercholesterolemia; mD, mean deviation; ROP, rate of glaucoma disease progression.

Prostaglandin analogue.

^†

Carbonic anhydrase inhibitor.

^‡

Beta blocker.

^§

Artificial tears.

^ǁ

α₂-Agonist.

^¶

Corticosteroid.

Nonsteroidal anti-inflammatory drug.

^**

Angiotensin receptor blocker.

^††

Statin.

^‡‡

Nonselective serotonin reuptake inhibitor.

^§§

Antipsychotic.

^ǁǁ

Calcium antagonist.

^¶¶

Fibrate.

^##

P2Y12-inhibitor.

^***

Antithromboticum.

^†††

Angiotensin converting enzyme inhibitor.

^‡‡‡

Diuretic.